Research progress and clinical application in the early diagnosis and treatment technology of hepatocellular carcinoma
10.3760/cma.j.cn501113-20250314-00093
- VernacularTitle:肝细胞癌早诊早治技术研究进展与临床应用
- Author:
Yuemin NAN
1
;
Suxian ZHAO
;
Lingdi LIU
Author Information
1. 河北医科大学第三医院中西医结合肝病科 河北医科大学第三医院消化内科，石家庄 050051
- Publication Type:Journal Article
- Keywords:
Hepatocellular carcinoma;
Early diagnosis;
Early therapy;
Research progress;
Clinical application
- From:
Chinese Journal of Hepatology
2025;33(4):307-309
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is a malignant tumor that endangers human health globally. Diagnosis and treatment at an early stage are the keys to receiving radical treatment and improving survival rates. A clinical solution for HCC diagnosis at an early stage is the combination of serum markers and imaging technology. A basic strategy for screening and diagnosis at an early stage with a favorable cost-effectiveness ratio is the alpha-fetoprotein combined with abdominal ultrasound. The HCC diagnostic rate at an early stage can be improved with AFP combined with des-gamma carboxy prothrombin, aldehyde-keto reductase 1B10, liquid biopsy, and imaging tests. The radical treatment for early-stage HCC has entered a new era of diversification. The effectiveness of radical treatment can assist in improving the combined use of small molecule targeted medications and immune checkpoint inhibitors. The prevention and control of liver cancer will move toward a new stage of greater precision and efficiency with the advancement of biotechnology and policy promotion.
